A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,656 shares of WVE stock, worth $19,998. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,656
Holding current value
$19,998
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$4.38 - $6.48 $16,013 - $23,690
3,656 New
3,656 $18,000
Q4 2023

Jan 24, 2024

SELL
$4.16 - $6.87 $212,700 - $351,263
-51,130 Reduced 59.01%
35,523 $179,000
Q3 2023

Oct 26, 2023

BUY
$3.56 - $5.75 $359 - $580
101 Added 0.12%
86,653 $498,000
Q2 2023

Aug 10, 2023

BUY
$3.51 - $4.69 $303,797 - $405,928
86,552 New
86,552 $315,000
Q2 2022

Jul 26, 2022

SELL
$1.23 - $3.25 $208,401 - $550,654
-169,432 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$2.0 - $3.28 $31,160 - $51,102
-15,580 Reduced 8.42%
169,432 $339,000
Q4 2021

Feb 08, 2022

BUY
$3.14 - $5.15 $142,844 - $234,283
45,492 Added 32.61%
185,012 $581,000
Q3 2021

Nov 15, 2021

BUY
$4.89 - $7.12 $128,220 - $186,693
26,221 Added 23.14%
139,520 $684,000
Q2 2021

Aug 11, 2021

BUY
$5.65 - $7.47 $133,181 - $176,082
23,572 Added 26.27%
113,299 $754,000
Q1 2021

May 13, 2021

BUY
$5.61 - $12.01 $228,753 - $489,719
40,776 Added 83.3%
89,727 $503,000
Q4 2020

Feb 10, 2021

BUY
$6.99 - $9.26 $157,750 - $208,979
22,568 Added 85.54%
48,951 $386,000
Q3 2020

Nov 12, 2020

BUY
$8.49 - $19.54 $70,950 - $163,295
8,357 Added 46.36%
26,383 $224,000
Q2 2020

Aug 11, 2020

BUY
$7.44 - $11.29 $54,750 - $83,083
7,359 Added 68.99%
18,026 $188,000
Q1 2020

May 12, 2020

BUY
$6.94 - $14.22 $74,028 - $151,684
10,667 New
10,667 $100,000

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $475M
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.